Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study-Reference-Cited by-同舟云学术

Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study

Published:2017 Issue:5 Volume:40 Page:645-649
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Ide Kazuki¹²³,Kawasaki Yohei¹³,Iketani Ryo³,Masaki Naohiko⁴

Affiliation:

1. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University

2. Center for the Promotion of Interdisciplinary Education and Research, Kyoto University

3. Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka

4. The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/40/5/40_b16-00941/_pdf

Reference23 articles.

1. 1) World Health Organization. “Hepatitis C. Fact sheet No. 164.”: ‹http://www.who.int/mediacentre/factsheets/fs164/en/›, cited 28 July, 2016.

2. 2) Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med., 368, 34–44 (2013).

3. 3) Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet, 383, 515–523 (2014).

4. 4) Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo HM, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis., 15, 645–653 (2015).

5. 5) Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state medicaid programs. Ann. Intern. Med., 163, 226–228 (2015).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective;Value in Health Regional Issues;2019-12

2. Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World;Journal of Managed Care & Specialty Pharmacy;2019-06